Keros Therapeutics Stock Piotroski F Score

KROS Stock  USD 11.22  0.22  1.92%   
This module uses fundamental data of Keros Therapeutics to approximate its Piotroski F score. Keros Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Keros Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Keros Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Keros Therapeutics Altman Z Score, Keros Therapeutics Correlation, Keros Therapeutics Valuation, as well as analyze Keros Therapeutics Alpha and Beta and Keros Therapeutics Hype Analysis.
For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.
  
At this time, Keros Therapeutics' Short and Long Term Debt Total is comparatively stable compared to the past year. Interest Debt Per Share is likely to gain to 0.53 in 2025, whereas Long Term Debt is likely to drop slightly above 4 M in 2025. At this time, Keros Therapeutics' Days Payables Outstanding is comparatively stable compared to the past year. Income Quality is likely to gain to 0.90 in 2025, whereas Price To Sales Ratio is likely to drop 158.59 in 2025.
At this time, it appears that Keros Therapeutics' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Unavailable
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Decrease

Focus
Long Term Debt Over Assets Change

Lower Leverage

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

Increase

Focus

Keros Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Keros Therapeutics is to make sure Keros is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Keros Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Keros Therapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00550.0058
Notably Down
Slightly volatile
Total Current Liabilities16.2 M27.4 M
Way Down
Slightly volatile
Non Current Liabilities Total17.7 M16.9 M
Sufficiently Up
Slightly volatile
Total Assets646.7 M615.9 M
Sufficiently Up
Slightly volatile
Total Current Assets618.3 M588.9 M
Sufficiently Up
Slightly volatile

Keros Therapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Keros Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Keros Therapeutics in a much-optimized way.

About Keros Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

7.65

At this time, Keros Therapeutics' Book Value Per Share is comparatively stable compared to the past year.

Keros Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap1.1B1.4B1.2B1.2B592.6M661.9M
Enterprise Value828.8M1.1B946.3M854.1M51.6M49.0M

Keros Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

About Keros Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.